Thoracic Oncologist, Chief of Heme/Onc @Georgetown @MedStarGUH, Head of Developmental Therapeutics @LombardiCancer, #DCLung26 #TexasLung27 #HereWeGo #LetsGoBucs
Georgetown, Washington, DC
Joined September 2011
- Tweets23.7K
- Following3.6K
- Followers30.7K
- Likes112K
Pinned Tweet
Pope Leo XIV already well on the road to recovery from his lung cancer surgery. I talked to @NewsCentralCNN about what we know and what we still need to know about the results for @Pontifex. We remain extremely optimistic about the path forward.
video.snapstream.net/Play/3b…
Stephen V Liu, MD retweeted
Can PD-(L)1xVEGF-A bispecifics redefine #LungCancer treatment? Find out as Drs. Liu (@StephenVLiu), Cascone, and Solomon (@bensolomon1) provide insights into where these therapies fit as research advances: bit.ly/4sYAHzL #MedEd
Stephen V Liu, MD retweeted
Breaking news: Pope Leo’s doctors said that the 71-year-old pontiff would require no further treatment for lung cancer after medical tests showed a malignant growth removed in surgery last week was “localized.” wapo.st/4k8k5Uu
Stephen V Liu, MD retweeted
New at #ESMO26: the ESMO Principles for Humanising Scientific Reporting.
Designed to strengthen the communication of oncology research while maintaining scientific rigour and patient relevance.
🔗 ow.ly/WzeJ50ZZIqH
Join us at #ESMO26 for the "Advancing the Frontiers of Lung Cancer Care" symposium, where I will discuss KRAS, SCLC, immunotherapy, and ADCs with Dr. @FSkoulidis, Dr. Margarita Majem, and @TerriConneran.
Monday, October 26, 13:00 CET, Oviedo Auditorium, Hall 5, IFEMA Madrid!
Stephen V Liu, MD retweeted
🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁
The abstracts our faculty picked as must-know from Madrid 👇
1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC
2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC
3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib
4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI
5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC
6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50%
7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC
8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months
9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI
🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC
#lcsm #OncoAlert #MedTwitter
Pinging our OncoAlert Lung Cancer Faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran
Stephen V Liu, MD retweeted
New multibillion deal to potentially bring innovative ADCs from China to our patients. 🎯 fiercebiotech.com/biotech/ro…
Stephen V Liu, MD retweeted
🚨 FDA grants accelerated approval to dostarlimab for untreated stage II/III dMMR/MSI-H rectal cancer. AZUR-1: investigator-assessed cCR12 68% ; 71% needed no surgery, RT, or chemotherapy and had no progression. A landmark organ-preservation step. @MikeFooteMD @MSKCancerCenter
Stephen V Liu, MD retweeted
Looking back on the DC Lung Cancer Conference 2026.
Grateful for the opportunity to connect with colleagues and friends who share a commitment to advancing lung cancer care. It was a pleasure to be part of this important conference and share a few words with such a dedicated community.
@pompili_cecilia @StephenVLiu
#LungCancer #ThoracicOncology
Phase II ETOP 18-21 AMAZE-lung trial of 2L amivantamab + lazertinib + bevacizumab after 3G TKI in EGFR NSCLC @LancetRespirMed. RR 39%. TRAEs included infusion reaction 58%, rash 50%, VTE 17% which would likely be mitigated with SQ and modern support.
thelancet.com/journals/lanre…
Stephen V Liu, MD retweeted
A smorgasbord of #RadOnc excellence at #AILCC26 featuring insights from:
- @gwalls89 SABR growth in NI, & new technology @BelfastTrust
- @rmcd22 on the superb @uniofgalway lung MDT
- @fifimcdrmh on RT in oligomet dx, SARON results due out @myESMO
@IrishLungCancer #LCSM – at Kildare, Ireland
Stephen V Liu, MD retweeted
A really excellent session with such high quality presentations.
Huge thanks to our international faculty for their help in this session and with the judging panel.
#AILCC26
Exciting Young Investigator Session at #AILCC26⭐️ Highlights:
- Mentorship 101 by @Alfdoc2: ‘the goal is to be successful, but how do we ensure we feel successful’
- 🏆 First prize #SileToland @CancerCentreIre
- 🏆 Runner up #HannahDodd @CancerInstIRE
@IrishLungCancer #LCSM
Stephen V Liu, MD retweeted
Exciting Young Investigator Session at #AILCC26⭐️ Highlights:
- Mentorship 101 by @Alfdoc2: ‘the goal is to be successful, but how do we ensure we feel successful’
- 🏆 First prize #SileToland @CancerCentreIre
- 🏆 Runner up #HannahDodd @CancerInstIRE
@IrishLungCancer #LCSM
Stephen V Liu, MD retweeted
Congratulations to @DrJNaidoo @gerryhanna @FordePatrick & Team for another excellent All Ireland Lung Cancer Conference 🫁 🇮🇪! A superb programme of clinical & translational presentations & posters from across the national and international lung cancer community.
#LCSM – at Dublin City, Ireland
Stephen V Liu, MD retweeted
As another All-Ireland Lung Cancer Conference comes to an end, a huge shout out to my 2 conference co-chairs @DrJNaidoo and @FordePatrick who are just the best to work with.
Delighted that the meeting has been a great success and huge 🙏 to all the Speakers, Chairs and supporting staff.
Thanks to all the Healtcare professionals and researchers from across Ireland who gave up their weekend to be there and make the meeting a success.
@cancertrials_ie
@CancerInstIRE
@CancerCentreIre
@TrinityMed1
Dr. @gerryhanna outlines the benefit of consolidation durvalumab in limited stage SCLC at #AILCC26.
Dr. @LochrinSarah reminds us that most patients with EGFR NSCLC have poor risk features and combination therapy needs to be considered up front. #AILCC26
Stephen V Liu, MD retweeted
Forward thinking talk by @PatelOncology on AI in healthcare and oncology
- learning the terminology of AI
- enhance use in areas to streamline workflows
- avoid ‘cognitive surrender’ for trainees & more- how does human intelligence preserve its creativity
#LCSM – at Kildare, Ireland
Stephen V Liu, MD retweeted
Superb talk at #AILCC26 from @StephenVLiu on the latest in SCLC:
- BiTEs: Tarla now a SOC in 2L (awaiting Irish approval) and new data due to come out at #ESMO26
- ADCs: B7H3 ADCs showing survival benefit in ph III trials (e.g: Tam-Peli), more to come
#LCSM
Brilliant peek into the translational advances in immunotherapy that have shaped current practice from Dr. Tina Cascone at #AILCC26. Powerful changes in our SoC rooted in foundational translational science and deep understanding. Impressive and humbling.
